NanoTemper named one of Germany’s most innovative companies in 2021 by Capital

For the second year in a row, NanoTemper was named one of the most innovative companies in Germany by Capital magazine. A five out of five star distinction placed NanoTemper in the ranking’s top quartile for innovation. And, with 76 of the 473 award-winning companies hailing from the Munich region, NanoTemper’s global headquarters is in an innovation hotspot.

More than 3200 experts were surveyed and asked to rate how innovative companies in their sectors were, ranging from the automotive and financial sector to the communications and technology industries. Notably, many of the winners for 2021 were pharmaceutical and tech companies. Biotech, especially, launched into the forefront of everyday people’s lives, and these companies were ready to respond to this need despite the limitations of the pandemic lockdowns.


“Our company has a crucial role in supporting those performing diagnostic and vaccine research during the pandemic, but we also have a responsibility to keep our own employees safe while moving forward. We struck that careful balance and continued to develop new products, like the Prometheus Panta, to help researchers do science that matters” — Philipp Baaske, co-CEO of NanoTemper


While innovation at NanoTemper is driven by a strong production, operations, and R&D team based out of the Munich headquarters, the company has offices in biotech hotspots all over the world, including the Bay Area, Boston, London, Shanghai, Beijing, Tokyo, and Bangalore. This physical presence is another key to innovative success according to co-CEO Dr. Stefan Duhr, “Our international locations and close connections to our customers allows us to identify their needs and pain points and thus to develop the best tools for them.”

Read the latest news and announcements from NanoTemper here.

About the Author

Stefanie Kall is a Product Marketing Manager with NanoTemper Technologies. She received a biochemistry PhD from University of Illinois in Chicago for her work characterizing inhibitors for kinases via X-ray crystallography. She also has a MSc in Biotechnology from Northwestern and a BSc from (The) Ohio State University in Biochemistry. During her free time, she enjoys running, baking, and playing video games.
Stefanie Kall